| Cytomegalovirus and herpesvirus research | Lifetime | 47 | BE 2 | 99.55 |
| Viral Infections and Immunology Research | Lifetime | 41 | BE 2 | 99.51 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 96 | BE 1 | 99.50 |
| COVID-19 Clinical Research Studies | Lifetime | 171 | BE 1 | 99.12 |
| Herpesvirus Infections and Treatments | Lifetime | 83 | BE 4 | 99.20 |
| Mosquito-borne diseases and control | Lifetime | 118 | BE 1 | 99.47 |
| Viral gastroenteritis research and epidemiology | Lifetime | 146 | BE 3 | 99.39 |
| Hepatitis C virus research | Lifetime | 178 | BE 2 | 99.44 |
| HIV/AIDS drug development and treatment | Lifetime | 189 | BE 7 | 99.21 |
| Viral Infections and Vectors | Lifetime | 268 | BE 4 | 99.03 |
| Biochemical and Molecular Research | Lifetime | 169 | BE 8 | 98.51 |
| Hepatitis B Virus Studies | Lifetime | 353 | BE 5 | 98.99 |
| HIV Research and Treatment | Lifetime | 507 | BE 8 | 98.70 |
| Viral-associated cancers and disorders | Lifetime | 300 | BE 3 | 98.26 |
| Virus-based gene therapy research | Lifetime | 771 | BE 10 | 97.91 |
| Respiratory viral infections research | Lifetime | 599 | BE 5 | 97.91 |
| Animal Virus Infections Studies | Lifetime | 612 | BE 14 | 97.36 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 304 | BE 6 | 97.03 |
| Animal Disease Management and Epidemiology | Lifetime | 693 | BE 20 | 96.86 |
| Viral Infections and Outbreaks Research | Lifetime | 455 | BE 5 | 96.06 |
| Quinazolinone synthesis and applications | Lifetime | 360 | BE 7 | 94.25 |
| Virology and Viral Diseases | Lifetime | 600 | BE 8 | 95.79 |
| Poxvirus research and outbreaks | Lifetime | 242 | BE 7 | 95.34 |
| SARS-CoV-2 detection and testing | Lifetime | 592 | BE 9 | 92.47 |
| Bioactive Natural Diterpenoids Research | Lifetime | 561 | BE 4 | 81.33 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 85 | BE 1 | 99.53 |
| Viral gastroenteritis research and epidemiology | 2021-2025 | 36 | BE 1 | 98.46 |
| COVID-19 Clinical Research Studies | 2021-2025 | 235 | BE 1 | 98.79 |
| Animal Virus Infections Studies | 2021-2025 | 66 | BE 2 | 97.17 |
| Viral Infections and Immunology Research | 2021-2025 | 74 | BE 1 | 95.73 |
| Mosquito-borne diseases and control | 2021-2025 | 211 | BE 2 | 96.44 |
| Viral Infections and Outbreaks Research | 2021-2025 | 143 | BE 2 | 93.21 |
| Respiratory viral infections research | 2021-2025 | 412 | BE 4 | 93.75 |
| Viral Infections and Vectors | 2021-2025 | 561 | BE 8 | 92.35 |
| SARS-CoV-2 detection and testing | 2021-2025 | 749 | BE 10 | 89.06 |
| vaccines and immunoinformatics approaches | 2021-2025 | 941 | BE 12 | 73.38 |
| Quinazolinone synthesis and applications | 2021-2025 | 966 | BE 8 | 51.55 |
| Alkaloids: synthesis and pharmacology | 2021-2025 | 964 | BE 7 | 39.22 |
